FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (145)Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer
Preheader (145)Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer
Arial
Text Analysis
Body Words132
Subject Words21
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px734 px
X-Spam Score-1.5
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening
